2UK Prospective Diabetes Study (UKPDS) Group. Intensive blood -glu- cose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UK- PDS 33) [J]. Lancet,1998, 352(9131) :837 - 853.
4Bouhon D,Tang A, Patel C, et al. Pharmacokinetics of the dipeptidyl peptidase -4 inhibitor saxagliptin in subjects with renal impairment[ J]. Endo Abstr,2009 ,20 :357.
8International Diabetes Federation.Foreword of the Diabetes Atlas(4th edition)[EB/OL].(2009-10-01)[2010-6-16].http://www.diabetesatlas.org/content/foreword-0.
9VanDeKoppel S,Choe HM,Sweet BV.Mana ged care perspective on three new agents for type 2 diabetes[J].J Manag Care Pharm,2008,14(4):363-380.
10Freeman JS.Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus[J].Cleve Clin J Med,2009,76(Suppl 5):S12-S19.
